Press Releases Imunon, Inc.

Equities

IMNN

US15117N6022

Delayed Nasdaq Other stock markets 12:07:41 2024-04-29 pm EDT			5-day change	1st Jan Change
1.44 ^USD	0.00%		+13.39%	+111.76%

Apr. 18	Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	MT
Apr. 18	Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101	Apr. 18	AQ
IMUNON Reports Compliance with Nasdaq Listing Requirements	Apr. 11	AQ
IMUNON Reports 2023 Financial Results and Provides Business Update	Mar. 28	AQ
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses	Mar. 25	AQ
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024	Mar. 21	AQ
IMUNON Files IND Application to Begin Human Testing of IMNN-101	Mar. 13	AQ
IMUNON Announces Leadership Change	Mar. 12	AQ
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5	Feb. 29	AQ
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer	Feb. 27	AQ
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine	Feb. 22	AQ
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Dec. 11	AQ
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023	Nov. 14	AQ
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update	Nov. 14	AQ
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023	Nov. 07	AQ
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress	23-10-23	AQ
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations	23-10-19	AQ
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer	23-10-18	AQ
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board	23-10-06	AQ
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer	23-09-28	AQ
IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies	23-09-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Imunon, Inc.

Equities

IMNN

US15117N6022

Press Releases

Filters